Sunovion Pharmaceuticals, Inc. will present new data analyses regarding its Brovana^® (arformoterol tartrate) Inhalation Solution, from clinical and health outcomes in chronic obstructive pulmonary disease (COPD) patients, at the 2016 American Thoracic Society (ATS) International Conference. The data analysis will be presented in poster form at the May 13-18 event in San Francisco, California.

Brovana (arformoterol tartrate) is used for nebulization-only, long-term, twice-daily maintenance treatment of bronchoconstriction in patients with moderate-to-severe COPD, including chronic bronchitis and emphysema.

Sunovion will present two post-hoc studies on data from a Phase 3 long-term safety and monitoring study that evaluated the efficacy of Brovana in COPD patients over a period of six months.

The poster presentations are:

• May 15, 9:00 a.m. – 11:00 a.m., Room 3024 (3^rdLevel), West Building, Moscone Center: “Chronic Obstructive Pulmonary Disease (COPD) – Related Hospitalizations by Health Status Response Among Patients Receiving Arformoterol Tartrate or Placebo: Post Hoc Analyses from a 52-Week Randomized, Controlled Study.” Look for poster #A1122.
• May 18, 11:00 a.m. – 12:45 p.m., Area A, Hall D (Lower Level), North Building, Moscone Center: “Health-Related Quality of Life Among Patients Who Experienced Prior COPD-Related Exacerbations: Post Hoc Analysis of a 52-Week Randomized Placebo-Controlled Trial of Nebulized Arformoterol Tartrate.” Look for poster #A6833.

Sunovian will also present the results of a prospective health study in COPD:

• May 15, 2016, 11:00 a.m. – 12:45 p.m., Area B, Hall D (Lower Level), North Building, Moscone Center: “Prevalence of Low Peak Inspiratory Flow Rate (PIFR) in Chronic Obstructive Pulmonary Disease (COPD) Patients At Discharge After an Exacerbation.” Look for poster #A1505.

In a press release, Krithika Rajagopalan, Sunovion’s Vice President and Head of Global Health Economics and Outcomes Research said COPD, a chronic and progressive disease affecting more than 15 million adults in the U.S., is the nation’s third leading cause of death.

“COPD exacerbations adversely impact a person’s quality of life, and also impose a substantial economic burden on the health system. Our aim is to provide treatments that can improve health outcomes for the COPD community, and the data being presented at ATS showcases Sunovion’s continued commitment to providing safe and effective treatment options for people with COPD,” Rajagopalan said.